Analysts Anticipate Acura Pharmaceuticals, Inc. (ACUR) Will Announce Earnings of -$0.12 Per Share
Analysts forecast that Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) will report earnings per share (EPS) of ($0.12) for the current quarter, Zacks reports. Zero analysts have issued estimates for Acura Pharmaceuticals’ earnings. Acura Pharmaceuticals reported earnings per share of ($0.19) in the same quarter last year, which would suggest a positive year-over-year growth rate of 36.8%. The company is scheduled to issue its next earnings results on Monday, November 13th.
On average, analysts expect that Acura Pharmaceuticals will report full year earnings of ($0.46) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of $0.38 per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Acura Pharmaceuticals.
Acura Pharmaceuticals (NASDAQ:ACUR) last announced its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.07. Acura Pharmaceuticals had a negative net margin of 2,335.87% and a negative return on equity of 1,237.56%. The business had revenue of $0.09 million for the quarter.
Shares of Acura Pharmaceuticals (NASDAQ ACUR) traded up 12.247% during midday trading on Friday, hitting $0.483. The stock had a trading volume of 8,183 shares. The stock’s 50-day moving average is $0.46 and its 200-day moving average is $0.52. The stock’s market cap is $10.04 million. Acura Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $1.87.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.